GlassScriptPhysician profile
Leslie A Morton
NPI 1528790425
$3,002.79
in general payments reported to CMS, 2019-2025
22 companies · $844 in 2025
The $844 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $84.62 · 2023: $899 · 2024: $1,175 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,918.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $523.17 | 2022-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $422.26 | 2023-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $376.82 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $241.33 | 2023-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $216.35 | 2023-2025 | Wainua, Farxiga |
| Amgen INC. | $201.76 | 2023-2025 | Repatha, Repatha |
| Novo Nordisk INC | $135.80 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.59 | 2024-2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $128.17 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $102.44 | 2024-2025 | Camzyos, Eliquis |
| Irhythm Technologies, INC. | $73.82 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Cvrx, INC. | $72.16 | 2025 | Barostim Neo System |
| Scpharmaceuticals INC. | $64.95 | 2024-2025 | |
| Boston Scientific Corporation | $55.64 | 2023 | Watchman Access System |
| Abiomed | $48.93 | 2024-2025 | Impella |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $45.81 | 2023-2024 | Verquvo |
| Medtronic, INC. | $45.66 | 2024 | Symplicity G3 |
| Bayer Healthcare Pharmaceuticals INC. | $38.74 | 2024-2025 | |
| Heartflow, INC. | $22.38 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.21 | 2025 | |
| Bridgebio Pharma, INC. | $19.62 | 2025 | Attruby |
| Abbvie INC. | $15.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Morton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.